The $70 million private placement financing will provide Pharvaris with additional capital to fund its clinical development programs and general corporate purposes. This influx of capital is likely to have a positive short-term impact on PHVS stock price as it demonstrates investor confidence in the company's growth potential and strengthens its financial position.